Survodutide, an experimental, unapproved weekly injection for obesity and fatty liver disease, copies two hormones: one curbs appetite, one pushes the liver to burn stored fat. Trials against placebo show substantial weight loss, better blood sugar control and less liver fat and inflammation. Nausea, vomiting and diarrhea are common during dose increases; resting heart rate rises slightly. Evidence is almost entirely developer-funded; no study has looked at lifespan or aging. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; percent change from own baseline | Primary effect |
| HbA1c | 4.0-5.6% | Glucose control |
| Fasting glucose | 70-99 mg/dL | Hypoglycemia on insulin or sulfonylureas |
| Triglycerides | Below 150 mg/dL | Lipid effect |
| ALT | About 7-55 U/L, lab-specific | Liver inflammation |
| Liver fat by MRI-PDFF | Below 5% | Liver-fat response |
| Resting heart rate | 60-100 beats per minute | Heart-rate increase |
| Blood pressure | No established target; change from own baseline and symptoms on standing | Hypotension; expected to fall |
| Creatinine and eGFR | Creatinine about 0.6-1.3 mg/dL | Kidney injury from fluid loss |
| Lipase and amylase | Below the lab's upper limit of normal | Pancreatitis |
| Lean mass by DEXA | No established target; appendicular lean mass change from own baseline | Lean-mass loss |
Cadence: Baseline before starting; weight, heart rate and blood pressure weekly at home during escalation; laboratory tests at 12 weeks, then every 3-6 months during the first year and every 6-12 months thereafter; liver imaging and DEXA at 12 months